A phase I trial assessing oral S-1 combined with fixed doses of irinotecan in advanced gastrointestinal malignancies (aGM) in 1st- or 2nd-line treatment.

e16189Background: S-1, an oral fluoropyrimidine, combined with Irinotecan (IRI) or Oxaliplatin (OX) (biweekly schedule) was assessed in Asian populations with acceptable safety profile and efficacy...